CytoDyn (CYDY) Other Operating Expenses (2010 - 2026)
CytoDyn's (CYDY) quarterly Other Operating Expenses came in at $4.6 million in Q1 2026, up 86.93% YoY from $2.5 million in Q1 2025, and down 76.63% on a QoQ basis from $19.9 million in Q4 2025.
CytoDyn (CYDY) Other Operating Expenses (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Other Operating Expenses data on file, last reported at $4.6 million in Q1 2026.
- Quarterly Other Operating Expenses rose 86.93% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $31.0 million (up 253.65% YoY) and the FY2025 annual result came in at -$16.9 million, changed N/A from the prior year.
- Other Operating Expenses fell to $4.6 million in Q1 2026, from $19.9 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $64.7 million in Q2 2022 to a low of -$24.0 million in Q3 2024.
- A 5-year average of $6.0 million and a median of $2.5 million in 2025 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2024 — Other Operating Expenses plunged 240560.0% — and 2025, when it jumped 35428.57%.
- Tracing CYDY's Other Operating Expenses over 5 years: stood at $18.0 million in 2022, then plunged by 99.96% to $8000.0 in 2023, then soared by 17512.5% to $1.4 million in 2024, then soared by 1311.57% to $19.9 million in 2025, then tumbled by 76.63% to $4.6 million in 2026.
- The last three Other Operating Expenses figures came in at $4.6 million (Q1 2026), $19.9 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 4.65 Mn |
| Nov 30, 2025 | 19.89 Mn |
| Aug 31, 2025 | 3.23 Mn |
| May 31, 2025 | 3.23 Mn |
| Feb 28, 2025 | 2.49 Mn |
| Nov 30, 2024 | 1.41 Mn |
| Aug 31, 2024 | -24.05 Mn |
| May 31, 2024 | -25,000.00 |
| Feb 29, 2024 | 7,000.00 |
| Nov 30, 2023 | 8,000.00 |
| Aug 31, 2023 | 10,000.00 |
| May 31, 2023 | 10,000.00 |
| Feb 28, 2023 | 12,000.00 |
| Nov 30, 2022 | 17.98 Mn |
| Aug 31, 2022 | 2.80 Mn |
| May 31, 2022 | 64.70 Mn |
| Feb 28, 2022 | 5.69 Mn |
| Aug 31, 2021 | -1.94 Mn |
| May 31, 2021 | 5.30 Mn |
| Feb 28, 2021 | 10.56 Mn |